Abstract
Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of fibrinolysis and regulates cell migration and fibrosis. Preclinical studies using genetically altered mice and biological or small molecule inhibitors have elucidated a role for PAI-1 in the pathogenesis of thrombosis, vascular remodeling, renal injury, and initiation of diabetes. Inhibition of PAI-1 is a potential therapeutic strategy in these diseases.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Atherosclerosis / drug therapy*
-
Atherosclerosis / metabolism
-
Fibrinolysis / drug effects*
-
Fibrinolysis / physiology
-
Humans
-
Indoleacetic Acids / pharmacology*
-
Kidney Diseases / drug therapy
-
Kidney Diseases / metabolism
-
Plasminogen Activator Inhibitor 1 / metabolism*
-
Pulmonary Fibrosis / drug therapy
-
Pulmonary Fibrosis / metabolism
-
Thrombosis / drug therapy*
-
Thrombosis / metabolism
Substances
-
Indoleacetic Acids
-
Plasminogen Activator Inhibitor 1
-
tiplaxtinin